Ciclesonide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchial Asthma
Conditions
Bronchial Asthma
Trial Timeline
Nov 1, 2011 → Aug 1, 2014
NCT ID
NCT01455194About Ciclesonide
Ciclesonide is a phase 3 stage product being developed by AstraZeneca for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01455194. Target conditions include Bronchial Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01455194 | Phase 3 | Completed |
| NCT00608218 | Pre-clinical | Completed |
| NCT00305461 | Phase 3 | Completed |
| NCT00261287 | Phase 3 | Completed |
| NCT00163371 | Phase 3 | Completed |
| NCT00163436 | Phase 3 | Completed |
| NCT00163488 | Phase 3 | Completed |
| NCT00163423 | Phase 3 | Completed |
| NCT00163319 | Phase 3 | Completed |
| NCT00163462 | Phase 3 | Completed |
| NCT00163514 | Phase 3 | Completed |
| NCT00163384 | Phase 3 | Completed |
| NCT00163397 | Phase 3 | Completed |
| NCT00163501 | Phase 3 | Completed |
| NCT00163345 | Phase 3 | Completed |
| NCT00163358 | Phase 3 | Completed |
| NCT00163410 | Phase 3 | Completed |
| NCT00163332 | Phase 3 | Completed |
| NCT00546520 | Phase 3 | Completed |
Competing Products
20 competing products in Bronchial Asthma